The hereditary nonpolyposis colorectal cancer syndrome: Genetics and clinical implications

被引:182
作者
Chung, DC
Rustgi, AK
机构
[1] Massachusetts Gen Hosp, Gastrointestinal Unit, GI Canc Genet Serv, Boston, MA 02114 USA
[2] Harvard Univ, Sch Med, Boston, MA 02115 USA
[3] Univ Penn, Sch Med, Philadelphia, PA 19104 USA
关键词
D O I
10.7326/0003-4819-138-7-200304010-00012
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Basic studies of DNA replication and repair have provided surprising and pivotal insights into a novel pathway of tumorigenesis. Defects in the DNA mismatch repair process dramatically increase the risk for specific types of cancer because of instability in microsatellite DNA sequences. A germline mutation in either the hMSH2 or hMLH1 mismatch repair gene results in the hereditary nonpolyposis colorectal cancer (HNPCC), or Lynch, syndrome. The lifetime risk for colon cancer is 80% in affected persons, and an aggressive cancer surveillance program is essential not only for these individuals but also for at-risk family members. The diagnosis of HNPCC can be made by fulfillment of the Amsterdam clinical criteria or through genetic testing for germline mutations in hMSH2 or hMLH1. Genetic testing is particularly useful in families with atypical clinical features and also for cancer risk assessment within an established HNPCC kindred. Microsatellite instability (MSI) of DNA is a hallmark feature of HNPCC-associated tumors, and as many as 15% of cases of sporadic colorectal cancer also display MSI. The biological behavior of colorectal tumors with MSI is distinctive; the most intriguing feature is their favorable natural history. The study of HNPCC has provided an example of the powerful interplay between molecular genetics and clinical care.
引用
收藏
页码:560 / 570
页数:11
相关论文
共 70 条
[1]   Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease [J].
Aaltonen, LA ;
Salovaara, R ;
Kristo, P ;
Canzian, F ;
Hemminki, A ;
Peltomäki, P ;
Chadwick, RB ;
Kääriäinen, H ;
Eskelinen, M ;
Järvinen, H ;
Mecklin, JP ;
de la Chapelle, A ;
Percesepe, A ;
Ahtola, H ;
Härkönen, N ;
Julkunen, R ;
Kangas, E ;
Ojala, S ;
Tulikoura, J ;
ValKamo, E .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (21) :1481-1487
[2]  
Aarnio M, 1999, INT J CANCER, V81, P214, DOI 10.1002/(SICI)1097-0215(19990412)81:2<214::AID-IJC8>3.3.CO
[3]  
2-C
[4]   REPLICON ORIGINS IN CHINESE-HAMSTER CELL DNA .2. REPRODUCIBILITY [J].
AMALDI, F ;
BUONGIOR.M ;
CARNEVALI, F ;
LEONI, L ;
MARIOTTI, D ;
POMPONI, M .
EXPERIMENTAL CELL RESEARCH, 1973, 80 (01) :79-87
[5]   Hemochromatosis: Diagnosis and management [J].
Bacon, BR .
GASTROENTEROLOGY, 2001, 120 (03) :718-725
[6]  
Boland CR, 1998, CANCER RES, V58, P5248
[7]   AUTORADIOGRAPHY OF HELA CELL DNA [J].
CAIRNS, J .
JOURNAL OF MOLECULAR BIOLOGY, 1966, 15 (01) :372-&
[8]   Choice of management strategy for colorectal cancer based on a diagnostic immunohistochemical test for defective mismatch repair [J].
Cawkwell, L ;
Gray, S ;
Murgatroyd, H ;
Sutherland, F ;
Haine, L ;
Longfellow, M ;
O'Loughlin, S ;
Cross, D ;
Kronborg, O ;
Fenger, C ;
Mapstone, N ;
Dixon, M ;
Quirke, P .
GUT, 1999, 45 (03) :409-415
[9]   Prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer [J].
Church, JM .
ANNALS OF MEDICINE, 1996, 28 (06) :479-482
[10]   Involvement of the mismatch repair system in temozolomide-induced apoptosis [J].
D'Atri, S ;
Tentori, L ;
Lacal, PM ;
Graziani, G ;
Pagani, E ;
Benincasa, E ;
Zambruno, G ;
Bonmassar, E ;
Jiricny, J .
MOLECULAR PHARMACOLOGY, 1998, 54 (02) :334-341